中文
As an innovative reagent in the field of organic synthesis, pyridinium tribromide is reshaping the production process of pharmaceutical intermediates with its outstanding performance. This reddish brown crystalline compound (CAS 39416-48-3) achieves a 98% selectivity breakthrough in the synthesis of key intermediates for antihistamines due to its highly selective bromination properties, with a sharp reduction in by-product content to below 0.5%. Its moisture sensitive design ensures stable storage in a dry environment, while the characteristic of releasing bromine when wet endows the reaction conditions with high controllability.
In the field of pharmaceutical synthesis, pyridinium tribromide exhibits three core advantages:
1. Precise and efficient: The bromination reaction of traditional high-temperature reflux process can be completed at room temperature, compressing the synthesis time of antibiotic intermediates from 8 hours to 3 hours and reducing energy consumption by 60%.
2. Stereoscopic specificity: Selective bromination of the alpha position of cyclohexanone can be achieved through solvent regulation, providing a key chiral intermediate for steroid drug synthesis.
3. Safe and controllable: The solid form avoids the risk of liquid bromine volatilization and can be safely operated in a fume hood, making it particularly suitable for large-scale production in GMP environments.
At present, the reagent has been successfully applied in the intermediate synthesis of heavyweight drugs such as brinzolamide and mifepristone, and its high purity characteristic (≥ 90%) ensures the impurity control of the final product. With the urgent demand for “efficient and low consumption” processes in the pharmaceutical industry, pyridinium tribromide is becoming the preferred bromination solution from laboratory to industrial production.